加拿大 - 英文 - Health Canada

apotex inc - pramipexole dihydrochloride monohydrate - tablet - 0.75mg - pramipexole dihydrochloride monohydrate 0.75mg - nonergot-derivative dopamine receptor agonists

加拿大 - 英文 - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.25mg - pramipexole dihydrochloride monohydrate 0.25mg - nonergot-derivative dopamine receptor agonists

加拿大 - 英文 - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.5mg - pramipexole dihydrochloride monohydrate 0.5mg - nonergot-derivative dopamine receptor agonists

加拿大 - 英文 - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 1mg - pramipexole dihydrochloride monohydrate 1mg - nonergot-derivative dopamine receptor agonists

加拿大 - 英文 - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 1.5mg - pramipexole dihydrochloride monohydrate 1.5mg - nonergot-derivative dopamine receptor agonists

加拿大 - 英文 - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.125mg - pramipexole dihydrochloride monohydrate 0.125mg - nonergot-derivative dopamine receptor agonists

美国 - 英文 - NLM (National Library of Medicine)

bryant ranch prepack - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, or 1.5 mg/kg/day) to pregna

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: mannitol; silicon dioxide; magnesium stearate; povidone; pregelatinised maize starch - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; mannitol; silicon dioxide; povidone - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; silicon dioxide; povidone; magnesium stearate; mannitol - pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary restless legs syndrome.